Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Depressive disorder | D003866 | EFO_1002014 | F32.A | 2 | 2 | — | — | — | 4 |
Depression | D003863 | — | F33.9 | — | 2 | — | — | — | 2 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 2 | — | — | — | 2 |
Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | — | 1 |
Traumatic stress disorders | D040921 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | ORVEPITANT |
INN | orvepitant |
Description | Orvepitant (GW823296) is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor. It was under development as a potential antidepressant drug, and early stage human clinical trials showed it to have some antidepressant effects, though not with sufficient efficacy to justify further development for this application. It was however considered a successful proof of concept for NK1 antagonists as potential antidepressants, and efforts are continuing to find more potent compounds which might be more effective.
|
Classification | Small molecule |
Drug class | tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cc1cc(F)ccc1[C@H]1C[C@@H](N2CCN3C(=O)CC[C@H]3C2)CCN1C(=O)N(C)[C@H](C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 |
PDB | — |
CAS-ID | 579475-18-6 |
RxCUI | — |
ChEMBL ID | CHEMBL2105667 |
ChEBI ID | — |
PubChem CID | 9852175 |
DrugBank | DB12427 |
UNII ID | IIU6V0W3JD (ChemIDplus, GSRS) |